| 1 |
29228628 |
10.18632/oncotarget.22178 |
2022 |
Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. |
JAK1 |
| 2 |
32431543 |
10.2147/CMAR.S242903 |
2022 |
Clinicopathological Characteristics and Mutational Profiling of Adult T-Cell Lymphoblastic Lymphoma in a Chinese Population. |
JAK1 |
| 3 |
33225311 |
10.1158/2643-3230.BCD-20-0051 |
2022 |
Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway. |
JAK1 |
| 4 |
33403355 |
10.1097/HS9.0000000000000516 |
2022 |
Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms. |
JAK1 |
| 5 |
33569430 |
10.21037/atm-20-7574 |
2022 |
Molecular profiling of Chinese systemic anaplastic large cell lymphoma patients: novel evidence of genetic heterogeneity. |
JAK1 |
| 6 |
33579790 |
10.1136/gutjnl-2020-322935 |
2022 |
Oncogenetic landscape of lymphomagenesis in coeliac disease. |
JAK1 |
| 7 |
33901030 |
10.1097/PAI.0000000000000936 |
2022 |
ALK-Negative Anaplastic Large Cell Lymphoma (ALCL): Prognostic Implications of Molecular Subtyping and JAK-STAT Pathway. |
JAK1 |
| 8 |
33980611 |
10.1158/1541-7786.MCR-21-0267 |
2022 |
EGR1 Addiction in Diffuse Large B-cell Lymphoma. |
JAK1 |
| 9 |
34521299 |
10.1080/10428194.2021.1969388 |
2022 |
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI). |
JAK1 |
| 10 |
34587248 |
10.1182/blood.2021012976 |
2022 |
Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL. |
JAK1 |
| 11 |
34653242 |
10.1182/blood.2021013379 |
2022 |
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. |
JAK1 |
| 12 |
34745769 |
10.1080/2162402X.2021.1995999 |
2022 |
Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner. |
JAK1 |
| 13 |
34997949 |
10.1096/fj.202101447R |
2022 |
TSLP up-regulates inflammatory responses through induction of autophagy in T cells. |
JAK1 |
| 14 |
35037568 |
10.1080/10428194.2021.2024819 |
2022 |
Current salvage therapies in Hodgkin lymphoma. |
JAK1 |
| 15 |
35100463 |
10.1111/cas.15277 |
2022 |
Inhibition of adult T-cell leukemia cell proliferation by polymerized proanthocyanidin from blueberry leaves through JAK proteolysis. |
JAK1 |
| 16 |
35101664 |
10.1016/j.bbrc.2022.01.070 |
2022 |
Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells. |
JAK1 |
| 17 |
35131871 |
10.1158/0008-5472.CAN-21-3386 |
2022 |
Transient Inhibition of the JAK/STAT Pathway Prevents B-ALL Development in Genetically Predisposed Mice. |
JAK1 |
| 18 |
35218354 |
10.1093/rheumatology/keac111 |
2022 |
Ruxolitinib Inhibits IFNγ-stimulated Sjögren's Salivary Gland MSC HLA-DR Expression and Chemokine-Dependent T-cell Migration. |
JAK1 |
| 19 |
35260349 |
10.1016/j.clml.2022.01.012 |
2022 |
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies. |
JAK1 |
| 20 |
35366115 |
10.1007/s00428-022-03309-4 |
2022 |
Cutaneous presentation of enteropathy-associated T-cell lymphoma masquerading as a DUSP22-rearranged CD30+ lymphoproliferation. |
JAK1 |
| 21 |
35418687 |
10.1038/s41586-022-04585-5 |
2022 |
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours. |
JAK1 |
| 22 |
35685993 |
10.21147/j.issn.1000-9604.2022.02.03 |
2022 |
Genomic landscape of T-cell lymphoblastic lymphoma. |
JAK1 |
| 23 |
35708139 |
10.3324/haematol.2022.281226 |
2022 |
Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome. |
JAK1 |
| 24 |
35776779 |
10.1371/journal.ppat.1010676 |
2022 |
STAT and Janus kinase targeting by human herpesvirus 8 interferon regulatory factor in the suppression of type-I interferon signaling. |
JAK1 |
| 25 |
35789258 |
10.1182/blood.2022015674 |
2022 |
Human complete NFAT1 deficiency causes a triad of joint contractures, osteochondromas, and B cell malignancy. |
JAK1 |
| 26 |
35805957 |
10.3390/ijms23136952 |
2022 |
Regulation of S100As Expression by Inflammatory Cytokines in Chronic Lymphocytic Leukemia. |
JAK1 |
| 27 |
35879049 |
10.1136/gutjnl-2021-326257 |
2022 |
Immunopathogenesis and environmental triggers in coeliac disease. |
JAK1 |
| 28 |
35920299 |
10.1096/fj.202200061RR |
2022 |
Mcm2 hypomorph leads to acute leukemia or hematopoietic stem cell failure, dependent on genetic context. |
JAK1 |
| 29 |
31711337 |
10.1080/10428194.2019.1688323 |
2021 |
Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis. |
JAK1 |
| 30 |
32185560 |
10.1007/s11894-020-0756-8 |
2021 |
Refractory Celiac Disease. |
JAK1 |
| 31 |
32297800 |
10.1080/10428194.2020.1749606 |
2021 |
Management of myelofibrosis after ruxolitinib failure. |
JAK1 |
| 32 |
32558259 |
10.1111/jcmm.15362 |
2021 |
Tubulosine selectively inhibits JAK3 signalling by binding to the ATP-binding site of the kinase of JAK3. |
JAK1 |
| 33 |
32560455 |
10.3390/cancers12061603 |
2021 |
A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries. |
JAK1 |
| 34 |
32767332 |
10.26355/eurrev_202008_22489 |
2021 |
MTMR2 promotes the progression of NK/T cell lymphoma by targeting JAK1. |
JAK1 |
| 35 |
32801162 |
10.1158/1541-7786.MCR-19-1098 |
2021 |
Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in <i>CRLF2</i>-Rearranged Ph-like ALL. |
JAK1 |
| 36 |
32843425 |
10.1101/mcs.a004994 |
2021 |
Failure of tofacitinib to achieve an objective response in a <i>DDX3X-MLLT10</i> T-lymphoblastic leukemia with activating <i>JAK3</i> mutations. |
JAK1 |
| 37 |
32998963 |
10.1158/1078-0432.CCR-20-1739 |
2021 |
Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy. |
JAK1 |
| 38 |
33168949 |
10.1038/s41375-020-01082-4 |
2021 |
Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets. |
JAK1 |
| 39 |
33222197 |
10.1111/bjh.17192 |
2021 |
Second primary malignancy in myelofibrosis patients treated with ruxolitinib. |
JAK1 |
| 40 |
33290262 |
10.18632/aging.202146 |
2021 |
The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development. |
JAK1 |
| 41 |
33307035 |
10.1016/j.ajpath.2020.12.001 |
2021 |
PIM Kinases Promote Survival and Immune Escape in Primary Mediastinal Large B-Cell Lymphoma through Modulation of JAK-STAT and NF-κB Activity. |
JAK1 |
| 42 |
33331925 |
10.1182/blood.2020005372 |
2021 |
Chromosome 20 loss is characteristic of breast implant-associated anaplastic large cell lymphoma. |
JAK1 |
| 43 |
33512474 |
10.1182/blood.2020006528 |
2021 |
CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1. |
JAK1 |
| 44 |
33523540 |
10.1111/ejh.13593 |
2021 |
Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series. |
JAK1 |
| 45 |
33544565 |
10.1097/PAS.0000000000001658 |
2021 |
Immunophenotypic Spectrum and Genomic Landscape of Refractory Celiac Disease Type II. |
JAK1 |
| 46 |
33643388 |
10.3389/fgene.2021.625414 |
2021 |
Identification of a 14-Gene Prognostic Signature for Diffuse Large B Cell Lymphoma (DLBCL). |
JAK1 |
| 47 |
33660353 |
10.1111/tbj.14205 |
2021 |
Next generation sequencing of breast implant-associated anaplastic large cell lymphomas reveals a novel STAT3-JAK2 fusion among other activating genetic alterations within the JAK-STAT pathway. |
JAK1 |
| 48 |
33705488 |
10.1371/journal.pone.0248298 |
2021 |
Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma. |
JAK1 |
| 49 |
33843403 |
10.1080/10428194.2021.1910684 |
2021 |
CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration. |
JAK1 |
| 50 |
33970999 |
10.1182/blood.2019000553 |
2021 |
Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma. |
JAK1 |
| 51 |
33971281 |
10.1016/j.canlet.2021.04.027 |
2021 |
Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia. |
JAK1 |
| 52 |
33994432 |
10.3960/jslrt.21001 |
2021 |
Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2<sup>V617F</sup>-myeloproliferative neoplasm. |
JAK1 |
| 53 |
34007050 |
10.1038/s41375-021-01291-5 |
2021 |
MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance. |
JAK1 |
| 54 |
34167562 |
10.1186/s13045-021-01114-1 |
2021 |
PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia. |
JAK1 |
| 55 |
34349069 |
10.11406/rinketsu.62.835 |
2021 |
[The road to treating chronic active Epstein-Barr viral infection]. |
JAK1 |
| 56 |
34359628 |
10.3390/cancers13153724 |
2021 |
Ruxolitinib as a Novel Therapeutic Option for Poor Prognosis T-LBL Pediatric Patients. |
JAK1 |
| 57 |
34391330 |
10.5070/D327754365 |
2021 |
Significant improvement of dermatitis herpetiformis with tofacitinib. |
JAK1 |
| 58 |
34535769 |
10.1038/s41388-021-02012-z |
2021 |
Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia. |
JAK1 |
| 59 |
34570764 |
10.1371/journal.pcbi.1009450 |
2021 |
Transcriptomic profiling in canines and humans reveals cancer specific gene modules and biological mechanisms common to both species. |
JAK1 |
| 60 |
34572893 |
10.3390/cancers13184667 |
2021 |
ALK-Negative Anaplastic Large Cell Lymphoma: Current Concepts and Molecular Pathogenesis of a Heterogeneous Group of Large T-Cell Lymphomas. |
JAK1 |
| 61 |
29541181 |
10.3892/ol.2018.7830 |
2020 |
Effects of purified <i>Omphalia lapidescens</i> protein on metastasis, cell cycle, apoptosis and the JAK-STAT signaling pathway in SGC-7901 human gastric cells. |
JAK1 |
| 62 |
30198914 |
10.1097/CAD.0000000000000692 |
2020 |
Effects of 9-cis-retinoic acid on the proliferation and apoptosis of cutaneous T-cell lymphoma cells. |
JAK1 |
| 63 |
30219772 |
10.3899/jrheum.171361 |
2020 |
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. |
JAK1 |
| 64 |
30333224 |
10.1158/1078-0432.CCR-18-1047 |
2020 |
Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies. |
JAK1 |
| 65 |
30715169 |
10.1093/asj/sjy311 |
2020 |
Genetics of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). |
JAK1 |
| 66 |
30715174 |
10.1093/asj/sjy250 |
2020 |
What Cytokines Can Tell Us About the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). |
JAK1 |
| 67 |
30997845 |
10.1080/10428194.2019.1594220 |
2020 |
Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. |
JAK1 |
| 68 |
31292115 |
10.1182/blood.2019001126 |
2020 |
Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. |
JAK1 |
| 69 |
31313387 |
10.1002/JLB.5RU0519-145R |
2020 |
JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. |
JAK1 |
| 70 |
31364141 |
10.26355/eurrev_201907_18457 |
2020 |
Effects of propofol on myocardial ischemia reperfusion injury through inhibiting the JAK/STAT pathway. |
JAK1 |
| 71 |
31382969 |
10.1186/s12964-019-0391-x |
2020 |
Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-κB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma. |
JAK1 |
| 72 |
31511358 |
10.4049/jimmunol.1900321 |
2020 |
Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes. |
JAK1 |
| 73 |
31570576 |
10.1073/pnas.1901382116 |
2020 |
IL-2 receptors preassemble and signal in the ER/Golgi causing resistance to antiproliferative anti-IL-2Rα therapies. |
JAK1 |
| 74 |
31575356 |
10.1177/1078155219878774 |
2020 |
Ruxolitinib for the treatment of lymphoma-associated hemophagocytic lymphohistiocytosis: A cautionary tale. |
JAK1 |
| 75 |
31655559 |
10.1186/s12885-019-6209-9 |
2020 |
The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data. |
JAK1 |
| 76 |
31774495 |
10.1182/blood.2019001904 |
2020 |
Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL. |
JAK1 |
| 77 |
31783811 |
10.1186/s12885-019-6381-y |
2020 |
Syndecan-1 suppresses cell growth and migration via blocking JAK1/STAT3 and Ras/Raf/MEK/ERK pathways in human colorectal carcinoma cells. |
JAK1 |
| 78 |
31788449 |
10.3389/fonc.2019.01186 |
2020 |
Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib. |
JAK1 |
| 79 |
31799703 |
10.1111/cei.13405 |
2020 |
The IL-2RG R328X nonsense mutation allows partial STAT-5 phosphorylation and defines a critical region involved in the leaky-SCID phenotype. |
JAK1 |
| 80 |
31833567 |
10.1002/hon.2701 |
2020 |
Myeloproliferative and lymphoproliferative disorders: State of the art. |
JAK1 |
| 81 |
31901912 |
|
2020 |
pSTAT3 and MYC in Epstein-Barr virus-positive diffuse large B-cell lymphoma. |
JAK1 |
| 82 |
31992840 |
10.1038/s41375-019-0685-4 |
2020 |
Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. |
JAK1 |
| 83 |
32058175 |
10.1016/j.leukres.2020.106313 |
2020 |
Risk of B-cell lymphoma in MPN patients treated with JAK1/2 inhibitors: Contradictory results? |
JAK1 |
| 84 |
32188095 |
10.3390/cancers12030702 |
2020 |
<i>STAT3</i> Mutation Is Associated with STAT3 Activation in CD30<sup>+</sup> ALK<sup>-</sup> ALCL. |
JAK1 |
| 85 |
32206779 |
10.1182/blood.2019002792 |
2020 |
Increased mTOR activation in idiopathic multicentric Castleman disease. |
JAK1 |
| 86 |
32631903 |
10.1128/MCB.00189-20 |
2020 |
Janus Kinase Mutations in Mice Lacking PU.1 and Spi-B Drive B Cell Leukemia through Reactive Oxygen Species-Induced DNA Damage. |
JAK1 |
| 87 |
33102814 |
10.1016/j.bbrep.2020.100832 |
2020 |
Cucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in Sézary cells. |
JAK1 |
| 88 |
33283700 |
10.19746/j.cnki.issn.1009-2137.2020.06.001 |
2020 |
[Gene Mutation in Acute Lymphoblastic Leukemia by DNA Sequencing]. |
JAK1 |
| 89 |
28356009 |
10.2174/1871520617666170327115657 |
2019 |
ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway. |
JAK1 |
| 90 |
28744013 |
10.1038/leu.2017.225 |
2019 |
The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling. |
JAK1 |
| 91 |
29262599 |
10.18632/oncotarget.21790 |
2019 |
Fusion of the genes ataxin 2 like, <i>ATXN2L</i>, and Janus kinase 2, <i>JAK2</i>, in cutaneous CD4 positive T-cell lymphoma. |
JAK1 |
| 92 |
29277359 |
10.1016/j.clml.2017.11.008 |
2019 |
SOHO State-of-the-Art Update and Next Questions: MPN. |
JAK1 |
| 93 |
29351986 |
10.3324/haematol.2017.180554 |
2019 |
A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. |
JAK1 |
| 94 |
29434279 |
10.1038/s41375-017-0004-x |
2019 |
Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma. |
JAK1 |
| 95 |
29479063 |
10.1038/s41375-018-0031-2 |
2019 |
High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement. |
JAK1 |
| 96 |
29515770 |
10.18632/oncotarget.24267 |
2019 |
Ruxolitinib significantly enhances <i>in vitro</i> apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model. |
JAK1 |
| 97 |
29562441 |
10.3760/cma.j.issn.0253-2727.2018.02.004 |
2019 |
[Spectrum of somatic mutations and their prognostic significance in adult patients with B cell acute lymphoblastic leukemia]. |
JAK1 |
| 98 |
29650799 |
10.1182/blood-2017-11-814913 |
2019 |
Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. |
JAK1 |
| 99 |
29689246 |
10.1016/j.humpath.2018.04.007 |
2019 |
IL-13 is produced by tumor cells in breast implant-associated anaplastic large cell lymphoma: implications for pathogenesis. |
JAK1 |
| 100 |
29695516 |
10.1182/blood-2017-10-812701 |
2019 |
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. |
JAK1 |
Datasets
Models
